Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir Dose-Response and Follow-up in HIV-1
NCT02249130Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 1999
- Primary completion
- Apr 2000
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Started Mar 1999; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02249130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249130.